Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressi...

por Holmgaard, Rikke B., Zamarin, Dmitriy, Lesokhin, Alexander, Merghoub, Taha, Wolchok, Jedd D.
Publicado 2016

Expression of indoleamine 2.3-dioxygenase by tumors induces local and systemic immunosuppressive effects in a murine melanoma model

por Holmgaard, Rikke B, Zamarin, Dmitriy, Munn, David H, Merghoub, Taha, Wolchok, Jedd D
Publicado 2014

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

por Holmgaard, Rikke B., Zamarin, Dmitriy, Munn, David H., Wolchok, Jedd D., Allison, James P.
Publicado 2013

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in anti-tumor T cell immunotherapy targeting CTLA-4

por Holmgaard, Rikke B, Zamarin, Dmitriy, Munn, David H, Wolchok, Jedd D, Allison, James P
Publicado 2013

Potentiation of immunomodulatory antibodies with oncolytic viruses for therapy of poorly-immunogenic tumors

por Zamarin, Dmitriy, Holmgaard, Rikke B, Plitt, Tamar, Allison, James, Merghoub, Taha, Wolchok, Jedd D
Publicado 2014

Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity

por Zamarin, Dmitriy, Holmgaard, Rikke B., Ricca, Jacob, Plitt, Tamar, Palese, Peter, Sharma, Padmanee, Merghoub, Taha, Wolchok, Jedd D., Allison, James P.
Publicado 2017

The PTEN pathway in T(regs) is a critical driver of the suppressive tumor microenvironment

por Sharma, Madhav D., Shinde, Rahul, McGaha, Tracy L., Huang, Lei, Holmgaard, Rikke B., Wolchok, Jedd D., Mautino, Mario R., Celis, Esteban, Sharpe, Arlene H., Francisco, Loise M., Powell, Jonathan D., Yagita, Hideo, Mellor, Andrew L., Blazar, Bruce R., Munn, David H.
Publicado 2015

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combinat...

por Holmgaard, Rikke B., Schaer, David A., Li, Yanxia, Castaneda, Stephen P., Murphy, Mary Y., Xu, Xiaohong, Inigo, Ivan, Dobkin, Julie, Manro, Jason R., Iversen, Philip W., Surguladze, David, Hall, Gerald E., Novosiadly, Ruslan D., Benhadji, Karim A., Plowman, Gregory D., Kalos, Michael, Driscoll, Kyla E.
Publicado 2018

Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor

por Yingling, Jonathan M., McMillen, William T., Yan, Lei, Huang, Huocong, Sawyer, J. Scott, Graff, Jeremy, Clawson, David K., Britt, Karen S., Anderson, Bryan D., Beight, Douglas W., Desaiah, Durisala, Lahn, Michael M., Benhadji, Karim A., Lallena, Maria J., Holmgaard, Rikke B., Xu, Xiaohong, Zhang, Faming, Manro, Jason R., Iversen, Philip W., Iyer, Chandrasekar V., Brekken, Rolf A., Kalos, Michael D., Driscoll, Kyla E.
Publicado 2017